摘要
胃癌发病率和死亡率一直居高不下。胃癌术后经常复发和远处转移,辅助治疗的价值已经没有争议。在亚洲,对于接受了标准D2手术的Ⅱ~Ⅲ期胃癌患者术后辅助化疗已经成为标准治疗,对于Ⅱ期患者口服S-1或XELOX联合化疗均可,而对于Ⅲb期及以上的高复发风险的胃癌患者应考虑使用XELOX方案化疗。在美国,采用D0和D1术比例较高,术后同步放化疗是目前适合的选择。欧美人群中,D2术式后采用辅助化疗还是辅助放化疗值得进一步研究。
The morbidity and mortality of gastric cancer has been high worldwide. Recurrence and distant metastasis after gastric cancer surgery often occur and the value of adjuvant treatment has no dispute. In Asia,adjuvant chemotherapy has become the standard treatment for patients with gastric cancer stage Ⅱ -Ⅲ after standard D2 resection. Single agent S-1 or XELOX combined chemotherapy regimen is used for patients stage Ⅱ ,while the XELOX combination regimen is optimal for the patients higher than or equal to stage Ⅲ b. In USA,postoperative chemoradiotherapy seems reasonable choice,because patients with DO and D1 resection account for high proportion. Adjuvant chemotherapy or chemoradiotherapy is optimal selection at present.
出处
《肿瘤学杂志》
CAS
2015年第2期90-92,共3页
Journal of Chinese Oncology
关键词
胃肿瘤
辅助化疗
辅助放化疗
预后
gastric neoplasms
chemotherapy,adjuvant
chemoradiotherapy,adjuvant
prognosis
